{
    "nctId": "NCT03581630",
    "briefTitle": "Effects of Mediterranean Diet and Naltrexone/Bupropion Treatment in Obese Breast Cancer Patients",
    "officialTitle": "Effects of Mediterranean Diet and Naltrexone/Bupropion Treatment on Body Weight and Metabolic Risk Factors in Obese Breast Cancer Patients After Breast Cancer Treatment",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Obesity, Overweight",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "PREVENTION",
    "enrollmentCount": 72,
    "primaryOutcomeMeasure": "Change in body weight",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Female, 20 to 65 years of age\n* Diagnosed with breast cancer stage \u2160-\u2162, and have completed cancer treatment including breast surgery and/or adjuvant chemotherapy, radiotherapy, hormonal therapy\n* BMI \u226525 kg/m2, or BMI \u226523 kg/m2 with one or more of the metabolic risk factors (waist circumference \u226580 cm, fasting glucose \u2265100 mg/dL, BP \u2265130/85 mmHg, HDL-cholesterol \\<50 mg/dL or controlled diabetes, hypertension, dyslipidemia with medications)\n* If woman of child bearing potential, agree to use effective contraception throughout the study period and 30 days after discontinuation of study drug\n* Able to speak and read Korean\n* Able to comply with all required study procedures and schedule\n* Willing and able to give written informed consent\n\nExclusion Criteria:\n\n* Participants with cancer recurrence or metastasis\n* Participants with uncontrolled hypertension (systolic blood pressure (SBP) \\>180 mmHg, or diastolic blood pressure (DBP) \\>120 mmHg)\n* Participants with hepatic disease (aspartate aminotransferase (AST)/alanine aminotransferase (ALT) \\>3 x institutional upper limit of normal) or renal disease (serum creatinine \\>2.0 mg/dL)\n* Participants with significant cardiovascular disease or stroke\n* Participants with history of seizures\n* Participants with serious psychiatric illness, including bipolar disorder, schizophrenia, or other psychosis, bulimia, anorexia nervosa, or suicidal ideation\n* Participants who are taking medications such as monoamine oxidase (MAO) inhibitors, opioid-containing medications, other naltrexone or bupropion containing medications, and Tamoxifen\n* Current smokers or use of nicotine replacement products in the previous 6 months\n* Pregnant or breast-feeding women\n* Any condition which in the opinion of the investigator makes the subject unsuitable for inclusion in this study",
    "sex": "FEMALE",
    "minimumAge": "20 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}